Supernus Pharmaceuticals' high P/E ratio is sustained by expectations of robust future growth, surpassing market average. Investors' belief in insignificant earnings deterioration risk bolsters the share price.
Caution is raised with substantial selling of Supernus Pharmaceuticals stock by key insiders and lack of buying in the past year. Insider ownership isn't high, indicating alignment with other shareholders. Evaluate carefully before purchasing due to these factors.
$スーパーナス ファーマシューティカルズ(SUPN.US)$ Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals for $8.10 a share in cash, or about $400 million, for two drugs approved for use in patients with Parkinson's disease. The transaction also includes two contingent value rights (CVR) with a total value of $1 per share in cash, or approximately $50 million. The initial cash consideration represents a premium of about 75% to Adamas' Oct. 8 closing share price.
スーパーナス ファーマシューティカルズに関するコメント
Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals for $8.10 a share in cash, or about $400 million, for two drugs approved for use in patients with Parkinson's disease. The transaction also includes two contingent value rights (CVR) with a total value of $1 per share in cash, or approximately $50 million. The initial cash consideration represents a premium of about 75% to Adamas' Oct. 8 closing share price.
まだコメントはありません